Abstract
While EBV PCR is used in the management of PTLD, the optimal primer set, relative importance of intracellular versus free plasma EBV, and the baseline profile in an organ transplant population remains unclear. We performed a prospective 2-arm trial utilizing an EBV PCR panel measuring LMP-1, EBER-1 and EBNA-1 in both free plasma as well as intracellular whole blood. Control Arm A consisted of 31 lung transplant patients and Arm B consisted of 35 transplant patients being evaluated for possible PTLD. In Arm A, 1/31 (3%) patients developed a transient plasma EBV load. Thirteen of 31 (42%) had detectable intracellular EBV. In Arm B, 17 (49%) patients were diagnosed with PTLD. Thirteen (76%) had EBV-positive PTLD with 12/13 (92%) having detectable EBV by PCR. The EBV PCR panel had a high sensitivity (92%), specificity (72%), positive predictive value (PPV) (71%) and negative predictive value (NPV) (93%) for diagnosing EBV-positive PTLD and followed patients' clinical course well (p < 0.001). Comparing the individual PCR assays, plasma EBNA PCR was superior with high sensitivity (77%), specificity (100%), PPV (100%) and NPV (86%). We conclude that EBV PCR is a useful test for managing PTLD patients. While plasma EBNA PCR is the best single assay for diagnosing and monitoring PTLD, the complete PCR panel is superior for ruling out its presence.
Original language | English |
---|---|
Pages (from-to) | 1016-1024 |
Number of pages | 9 |
Journal | American Journal of Transplantation |
Volume | 8 |
Issue number | 5 |
DOIs | |
State | Published - May 2008 |
Externally published | Yes |
Keywords
- Blood
- Diagnosis
- Diagnostic markers
- Epstein-Barr virus (EBV)
- Lung transplantation
- Lymphoma
- Malignancy
- Monitoring
- Polymerase chain reaction
- Posttransplant lymphoproliferative disease
- Posttransplant lymphoproliferative disorders
- Therapy